Abstract
Pharmacogenetics has progressively become a major concern in personalized medicine. The development of modern technologies in genetic testing and cost-effectiveness have rendered genotyping strategies easy to perform comparing to time-consuming phenotyping methods. In oncology, canonical markers such TPMT, DPYD or UGT1A1 are routinely included in clinical practice but their use is still controversial partly because of insufficient genotype to phenotype correlation. The next challenge is to accurately translate genotype-phenotype correlations into clinically useful diagnostics, and clinically useful leads concerning new therapeutic targets. Besides, recent studies have focused on emerging genetic variants of ADME genes such cytidine deaminase (CDA) or pregnane X receptor (PXR) that could be of interest for predicting anticancer drug response or toxicity. The candidate gene approach “metabolism guided” now evolves towards more global strategies thanks to genome resequencing projects such HapMap that have considerably increased our knowledge of genetics variations in humans. Multiplexed genotyping methods make possible the set-up of panels of candidate or tag SNPs for subsequent haplotypic analysis. Last, genome-wide association studies (GWAS) are feasible when large cohort of patients is available to identify new loci associated with drug response or adverse drug reactions or to definitively confirm the role of candidate genetic variations.
Keywords: Pharmacogenetics, drug metabolizing enzymes and transporters, haplotype, GWAS
Current Topics in Medicinal Chemistry
Title:Genetic Polymorphisms of Drug Metabolizing Enzymes and Transporters: The Long Way from Bench to Bedside
Volume: 12 Issue: 15
Author(s): Alexandre Evrard and Litaty Mbatchi
Affiliation:
Keywords: Pharmacogenetics, drug metabolizing enzymes and transporters, haplotype, GWAS
Abstract: Pharmacogenetics has progressively become a major concern in personalized medicine. The development of modern technologies in genetic testing and cost-effectiveness have rendered genotyping strategies easy to perform comparing to time-consuming phenotyping methods. In oncology, canonical markers such TPMT, DPYD or UGT1A1 are routinely included in clinical practice but their use is still controversial partly because of insufficient genotype to phenotype correlation. The next challenge is to accurately translate genotype-phenotype correlations into clinically useful diagnostics, and clinically useful leads concerning new therapeutic targets. Besides, recent studies have focused on emerging genetic variants of ADME genes such cytidine deaminase (CDA) or pregnane X receptor (PXR) that could be of interest for predicting anticancer drug response or toxicity. The candidate gene approach “metabolism guided” now evolves towards more global strategies thanks to genome resequencing projects such HapMap that have considerably increased our knowledge of genetics variations in humans. Multiplexed genotyping methods make possible the set-up of panels of candidate or tag SNPs for subsequent haplotypic analysis. Last, genome-wide association studies (GWAS) are feasible when large cohort of patients is available to identify new loci associated with drug response or adverse drug reactions or to definitively confirm the role of candidate genetic variations.
Export Options
About this article
Cite this article as:
Evrard Alexandre and Mbatchi Litaty, Genetic Polymorphisms of Drug Metabolizing Enzymes and Transporters: The Long Way from Bench to Bedside, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531388
DOI https://dx.doi.org/10.2174/156802612803531388 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Surgical Treatment in FIGO Stage I Cervical Cancer: Evolution of Concepts
Current Women`s Health Reviews Probiotics in Female Reproductive Health: Paradigms, Prospects and Challenges
Current Women`s Health Reviews Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design PCR Detection and Sequencing of <i>Trichomonas vaginalis</i> in Women with Suspected Vaginitis in Southwestern Iran
Infectious Disorders - Drug Targets Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Origin and Evolution of China Pharmacopoeia and Its Implication for Traditional Medicines
Mini-Reviews in Medicinal Chemistry All for Statins and Statins for All; An Update
Current Pharmaceutical Design Transmission Electron Microscopy as Key Technique for the Characterization of Telocytes
Current Stem Cell Research & Therapy Gonadotropin-Releasing Hormone Receptor System: Modulatory Role in Aging and Neurodegeneration
CNS & Neurological Disorders - Drug Targets Nasal Drug Delivery System-Factors Affecting and Applications
Current Drug Therapy Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials Disorders of Sex Development: A Review
Current Women`s Health Reviews Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Endometriosis: The Role of Pharmacotherapy
Current Women`s Health Reviews Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine Biomolecular Pathogenesis of Borderline Ovarian Tumors: Focusing Target Discovery Through Proteogenomics
Current Cancer Drug Targets The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Current Drug Targets